Table 3. Comparison of changes in clinical parameters and anemia therapy prescription patterns between baseline and SO 4 – 6 for patients with 4 – 6 months of SO follow-up (n = 424).
| Parameter | Baseline | SO 4-6 | p-value |
|---|---|---|---|
| Pill burden | |||
| Prescribed PB pills/day | 9.7 ± 4.4 | 4.0 ± 1.4 | < 0.001 |
| MBD markers | |||
| Patients with serum phosphorus ≤ 5.5 mg/dL, n (%) | 66 (15.6) | 129 (30.4) | < 0.001 |
| Serum phosphorus, mg/dL | 6.86 ± 1.44 | 6.41 ± 1.61 | < 0.001 |
| Serum calcium, mg/dL | 9.24 ± 0.70 | 9.11 ± 0.72 | < 0.001 |
| iPTH, pg/mL | 608.5 ± 524.9 | 652.7 ± 543.7 | 0.03 |
| Clearance and nutritional parameters | |||
| Albumin, g/dL | 3.98 ± 0.30 | 3.97 ± 0.31 | 0.08 |
| enPCR, g/kg/day | 0.96 ± 0.2 | 0.94 ± 0.2 | 0.01 |
| eKT/V | 1.46 ± 0.21 | 1.45 ± 0.21 | 0.5 |
| Patients receiving IV iron therapy (n = 393)a | |||
| Iron indices | |||
| Ferritin, ng/mL | 984.1 ± 484.6 | 1,070.7 ± 510.1 | < 0.001 |
| TSAT, % | 34.3 ± 11.1 | 35.7 ± 12.4 | 0.09 |
| Hemoglobin, g/dL | 10.9 ± 1.0 | 10.9 ± 1.1 | 0.5 |
| Anemia therapy medications | |||
| IV iron use, n (%)a | 331 (84.2) | 276 (70.2) | < 0.001 |
| Iron sucrose use, n (%) | 330 (99.7) | 265 (96) | < 0.001 |
| Iron sucrose dose, mg/week | 67.8 ± 44.3 | 58.2 ± 39.5 | 0.02 |
| ESA use, n (%)b | 339 (86.3) | 323 (82.2) | 0.01 |
| Epoetin-α use, n (%) | 321 (94.7) | 281 (87) | < 0.001 |
| Epoetin-α dose, U/HD Tx | 3,613 ± 3,330 | 3,182 ± 3,379 | 0.03 |
| Epoetin-α dose, U/administration | 5,397 ± 4,581 | 4,805 ± 4,116 | 0.02 |
| Patients not receiving IV iron therapy (n = 31)a | |||
| Iron indices | |||
| Ferritin, ng/mL | 1161.1 ± 673.8 | 926.5 ± 572.9 | 0.005 |
| TSAT, % | 38.3 ± 15.3 | 38.9 ± 16.0 | 0.7 |
| Hemoglobin, g/dL | 12.0 ± 1.7 | 12.1 ± 1.7 | 0.5 |
| Anemia therapy medications | |||
| ESA use, n (%)b | 14 (45.2) | 12 (38.7) | 0.3 |
| Epoetin-α use, n (%) | 14 (100) | 11 (91.7) | 0.2 |
| Epoetin-α dose, U/HD Tx | 4,480 ± 4,813 | 3,851 ± 4,597 | 0.3 |
| Epoetin-α dose, U/administration | 5,689 ± 5,171 | 4,989 ± 4,600 | 0.4 |
Values are expressed as mean ± SD or number (%) of patients. aIV iron treatment includes iron sucrose, ferumoxytol, and sodium ferric gluconate; bESA treatment includes epoetin-α, epoetin-β and methoxy polyethylene glycol, and darbepoetin-α; ESA= erythropoiesis stimulating agent; iPTH = intact parathyroid hormone; IV = intravenous; MBD = mineral bone disease; PB = phosphate binder; enPCR = equilibrated normalized protein catabolic rate; SD = standard deviation; SO = sucroferric oxyhydroxide; TSAT = transferrin saturation; Tx = treatment.